Profile data is unavailable for this security.
About the company
Merus NV is the Netherlands - based biotechnology company, concentrated on developing differentiating therapeutics for cancer patients. The product programs in the Merus pipeline are based on the Multiclonics format. Its products are designed to bind to multiple targets, and are manufactured with features for anti-cancer effects against the complex mechanisms that drive cancer. Company's products engage cancer antigens and harness the power of the immune system to kill tumor cells by utilizing technology platform. One of the drug zenocutuzumab (Zeno), a Biclonics antibody, concentrates on helping patients with lung, pancreatic and other types of solid tumors. The company operates in the Netherlands and United States.
- Revenue in USD (TTM)43.95m
- Net income in USD-154.94m
- Incorporated2003
- Employees172.00
- LocationMerus NVUppsalalaan 17, 3rd & 4th floorUTRECHT 3584 CTNetherlandsNLD
- Phone+31 850162500
- Websitehttps://merus.nl/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Guardant Health Inc | 563.95m | -479.45m | 2.20bn | 1.78k | -- | 13.87 | -- | 3.91 | -4.28 | -4.28 | 5.04 | 1.30 | 0.3321 | 4.00 | 6.06 | 317,002.80 | -28.23 | -22.26 | -31.99 | -24.59 | 59.74 | 64.62 | -85.02 | -97.07 | 6.24 | -12.04 | 0.8778 | -- | 25.45 | 44.14 | 26.76 | -- | 0.2786 | -- |
| Denali Therapeutics Inc | 330.53m | -145.22m | 2.22bn | 445.00 | -- | 2.09 | -- | 6.71 | -1.09 | -1.09 | 2.39 | 7.45 | 0.2529 | -- | -- | 742,766.30 | -11.11 | -14.98 | -13.37 | -17.71 | -- | -- | -43.94 | -104.50 | -- | -- | 0.00 | -- | 204.74 | 20.67 | 55.45 | -- | 30.70 | -- |
| Arvinas Inc | 78.50m | -367.30m | 2.22bn | 445.00 | -- | 3.35 | -- | 28.32 | -6.62 | -6.62 | 1.45 | 9.71 | 0.061 | -- | 157.00 | 176,404.50 | -28.35 | -22.01 | -36.10 | -26.47 | -- | -- | -464.71 | -316.55 | -- | -- | 0.0012 | -- | -40.26 | 40.53 | -30.02 | -- | 0.4852 | -- |
| Vericel Corp | 197.52m | -3.18m | 2.23bn | 314.00 | -- | 9.76 | 1,423.63 | 11.29 | -0.0684 | -0.0684 | 4.15 | 4.72 | 0.6304 | 4.26 | 3.77 | 629,031.90 | -1.02 | -3.07 | -1.17 | -3.50 | 68.64 | 67.87 | -1.61 | -4.49 | 4.21 | -- | 0.0004 | -- | 20.17 | 16.80 | 80.96 | -- | 59.35 | -- |
| Corcept Therapeutics Incorporated | 482.38m | 106.14m | 2.33bn | 352.00 | 23.56 | 4.59 | 21.78 | 4.84 | 0.9542 | 0.9542 | 4.32 | 4.90 | 0.8007 | 0.9374 | 13.37 | 1,370,384.00 | 17.62 | 21.17 | 20.65 | 23.85 | 98.66 | 98.52 | 22.00 | 27.23 | 4.31 | -- | 0.00 | 0.00 | 20.04 | 13.93 | 4.66 | 7.08 | -14.15 | -- |
| Avidity Biosciences Inc | 9.56m | -212.22m | 2.38bn | 253.00 | -- | 3.97 | -- | 249.18 | -2.90 | -2.90 | 0.131 | 6.32 | 0.0151 | -- | -- | 37,786.56 | -33.49 | -31.61 | -37.40 | -34.45 | -- | -- | -2,219.88 | -1,540.50 | -- | -- | 0.00 | -- | 3.64 | 90.71 | -21.97 | -- | 143.89 | -- |
| Celldex Therapeutics, Inc. | 6.88m | -141.43m | 2.38bn | 160.00 | -- | 4.82 | -- | 346.39 | -2.91 | -2.91 | 0.1421 | 7.68 | 0.0168 | -- | 4.63 | 43,018.75 | -34.56 | -29.65 | -36.80 | -31.42 | -- | -- | -2,054.76 | -1,747.94 | -- | -- | 0.00 | -- | 192.02 | -6.32 | -25.91 | -- | 17.46 | -- |
| CG Oncology Inc | 204.00k | -67.80m | 2.40bn | 61.00 | -- | -- | -- | 11,775.67 | -1.07 | -1.07 | 0.0032 | 2.91 | -- | -- | -- | 3,344.26 | -- | -- | -- | -- | -- | -- | -23,826.96 | -- | -- | -- | 0.002 | -- | 6.81 | -- | -54.83 | -- | -- | -- |
| Rhythm Pharmaceuticals Inc | 77.43m | -184.68m | 2.42bn | 226.00 | -- | 13.90 | -- | 31.27 | -3.19 | -3.19 | 1.34 | 2.86 | 0.2165 | 1.61 | 7.34 | 342,601.80 | -51.64 | -47.21 | -59.55 | -52.84 | 87.99 | -- | -238.52 | -681.38 | 5.43 | -- | 0.3847 | -- | 227.56 | -- | -1.97 | -- | -42.10 | -- |
| Merus NV | 43.95m | -154.94m | 2.46bn | 172.00 | -- | 6.81 | -- | 56.05 | -2.99 | -2.99 | 0.8519 | 6.16 | 0.1056 | -- | 13.56 | 255,505.80 | -37.24 | -29.35 | -45.30 | -35.36 | -- | -- | -352.56 | -252.21 | -- | -- | 0.00 | -- | 5.68 | 2.75 | -18.10 | -- | -1.73 | -- |
| Janux Therapeutics Inc | 8.08m | -58.29m | 2.49bn | 64.00 | -- | 6.48 | -- | 308.12 | -1.34 | -1.34 | 0.1837 | 7.44 | 0.0217 | -- | -- | 126,296.90 | -15.66 | -- | -16.31 | -- | -- | -- | -721.18 | -- | -- | -- | 0.00 | -- | -6.14 | -- | 7.56 | -- | -- | -- |
| Summit Therapeutics Inc | 0.00 | -614.93m | 2.52bn | 105.00 | -- | 32.42 | -- | -- | -1.54 | -1.54 | 0.00 | 0.1107 | 0.00 | -- | -- | 0.00 | -141.83 | -77.32 | -152.22 | -86.35 | -- | -- | -- | -20,989.46 | -- | -110.40 | 0.5628 | -- | -100.00 | -- | -680.54 | -- | -4.84 | -- |
| Hims & Hers Health Inc | 872.00m | -23.55m | 2.64bn | 1.05k | -- | 7.66 | -- | 3.03 | -0.1131 | -0.1131 | 4.17 | 1.61 | 2.16 | 7.13 | 195.17 | 833,652.00 | -5.83 | -- | -7.02 | -- | 81.99 | -- | -2.70 | -- | 2.74 | -- | 0.00 | -- | 65.49 | -- | 64.15 | -- | -- | -- |
| Neogen Corp | 929.24m | 1.57m | 2.68bn | 2.64k | 1,715.67 | 0.8517 | 22.73 | 2.88 | 0.0072 | 0.0072 | 4.29 | 14.52 | 0.2044 | 2.79 | 5.81 | 351,984.10 | 0.0345 | 3.44 | 0.0355 | 3.62 | 50.97 | 47.25 | 0.1685 | 7.77 | 2.66 | 1.40 | 0.2205 | 0.00 | 56.01 | 15.63 | -147.34 | -- | 25.71 | -- |
| MoonLake Immunotherapeutics | 0.00 | -36.01m | 2.71bn | 50.00 | -- | 5.18 | -- | -- | -0.7623 | -0.7623 | 0.00 | 8.20 | 0.00 | -- | -- | 0.00 | -14.61 | -- | -16.09 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 27.95 | -- | -- | -- |
| Apogee Therapeutics Inc | 0.00 | -83.99m | 2.72bn | 91.00 | -- | 5.92 | -- | -- | -1.74 | -1.74 | 0.00 | 7.86 | -- | -- | -- | 0.00 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -111.10 | -- | -- | -- |
Data as of Apr 25 2024. Currency figures normalised to Merus NV's reporting currency: US Dollar USD
40.16%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Commodore Capital LPas of 31 Dec 2023 | 4.75m | 8.20% |
| Samlyn Capital LLCas of 31 Dec 2023 | 3.41m | 5.90% |
| BVF Partners LPas of 31 Dec 2023 | 2.75m | 4.76% |
| RTW Investments LPas of 31 Dec 2023 | 2.37m | 4.10% |
| Federated Global Investment Management Corp.as of 29 Feb 2024 | 2.30m | 3.97% |
| Wellington Management Co. LLPas of 31 Dec 2023 | 2.01m | 3.47% |
| Franklin Advisers, Inc.as of 31 Dec 2023 | 1.88m | 3.24% |
| Driehaus Capital Management LLCas of 31 Dec 2023 | 1.31m | 2.27% |
| Balyasny Asset Management LPas of 31 Dec 2023 | 1.23m | 2.13% |
| Pictet Asset Management SAas of 31 Dec 2023 | 1.23m | 2.13% |
More ▼
Data from 31 Dec 2023 - 31 Dec 2023Source: FactSet Research Systems Inc.
